Consecutive Affinity and Ion-Exchange Chromatography for AAV9 Vectors Purification
<b>Background:</b> Irrespective of the rapid development of AAV-based gene therapy, the production of clinical-grade vectors has a bottleneck resulting from product-related impurities such as empty and partially filled capsids, which lack a functional recombinant genome. <b>Methods:</b> In the current study, we applied the sequential affinity chromatography (AC)- and anion-exchange chromatography (AEX)-based method for purification of AAV9 vector harboring single-stranded genome encoding the fusion of firefly luciferase (fLuc)-yellow fluorescent protein (YFP) under chicken beta actin (CBA) promoter. We assessed the efficiency of two different pre-packed cross-linked sepharose and one monolithic AEX columns following AC purification to separate fully encapsulated with recombinant DNA AAV vectors from byproducts. <b>Results:</b> We showed the possibility to achieve approximately 20-80% recovery and over 90% calculated DNA-containing/empty capsid ratio depending on column and buffers composition. Additionally, we confirmed the infectivity of AAV by in vitro luciferase assay regardless of recovery method from different AEX columns. <b>Conclusions:</b> Our purification data indicate the effectiveness of dual chromatography method to obtain rAAV9 vectors with DNA-containing capsid content over 90%.
Authors
- George Aslanidi (ORCID: https://orcid.org/0000-0002-2726-8627)
- Ozgun F. Duzenli (ORCID: https://orcid.org/0000-0002-7665-0726)
Institutions
- University of Minnesota (US)
- Hormel (United States) (US)
Publication Details
- Journal
- Biomedicines
- Published
- 2025-02-05
- DOI
- https://doi.org/10.3390/biomedicines13020361
- Citations
- 9
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 16.36
Funders
- U.S. Food and Drug Administration